Aitia brings together supercomputing power, our proven causal AI reverse-engineering forward-simulation (REFS) engine, and massive patient multiomics and clinical datasets to build Gemini Digital Twins, in silico models of human disease biology that inform drug discovery and development at every step of the biopharma pipeline.
Understanding the molecular interactions that cause diseases reveals a set of novel potential intervention points. These findings can be used by our biopharma partners to discover, develop, and throughly test (in the bench and the clinic) newly discovered and precisely targeted drugs.
Aitia’s causal AI-based Gemini Digital Twins lead to differentiated and novel partnered programs across multiple diseases with high unmet medical need.
Our technology, data, and expertise in generating deep biological knowledge dovetails perfectly with our partner’s own data and pharmaceutical R&D expertise to accelerate the discovery and development of new therapies for multiple areas of unmet medical need, e.g., oncology, neuro-degeneration, immunological, and cardiometabolic diseases.
